|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Akeso’s lung cancer drug reduced the risk of death by 34% compared to standard care in previously untreated Chinese patients — a huge win in a hotly contested class of drugs. Max Gelman reports on the results, as well as the caveats that mean it won’t change practice in the US, at least not yet. |
|
|
|
Karen Weintraub |
Deputy Editor, Endpoints News
|
|
|
|
 |
|
|
|
by Max Gelman
|
CHICAGO —The leading drug in biopharma's hottest immunotherapy race reduced the risk of death by 34% in previously untreated Chinese lung cancer patients, compared... | |
|
|
|
|
|
|
by Lei Lei Wu
|
CHICAGO— When oncologist Brian Wolpin saw the positive results from Revolution Medicines' pivotal pancreatic cancer study for the first time, he was rendered speechless... | |
|
|
|
|
|
|
by Ryan Cross
|
Personalized cancer vaccinesmight make notoriously deadly brain cancers more susceptible to immunotherapy and possibly prolong survival for some patients, according to new research
from... | |
|
|
|
|
|
|
by Lei Lei Wu
|
CHICAGO— Grail's blood test, which it has pitched as a way to spot a variety of cancers early in their growth, still isn't ready... | |
|
|
|
|
|
|
|
Worldwide made. Thanks for reading.
|
|
|
|
|
|
|
|
